The impact of CD34+ cell dose on platelet engraftment in pediatric patients following unmanipulated haploidentical blood and marrow transplantation

Pediatric Blood and Cancer

Volumn 53, Issue 6, 2009, Pages 1100-1106

  Chang, Ying Jun ^a   Xu, Lan Ping ^a   Liu, Dai Hong ^a   Liu, Kai Yan ^a   Han, Wei ^a   Chen, Yu Hong ^a   Wang, Yu ^a   Chen, Huan ^a   Wang, Jing Zhi ^a   Zhang, Xiao Hui ^a   Zhao, Xiang Yu ^a   Huang, Xiao Jun ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

CD34+ cells; Engraftment; Pediatric; Unmanipulated blood and marrow transplantation

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; FIBROBLAST GROWTH FACTOR RECEPTOR 4; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SEMUSTINE; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CHILDHOOD DISEASE; CHRONIC MYELOID LEUKEMIA; ENGRAFTMENT; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HAPLOIDY; HEMATOPOIESIS; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; ORGAN DONOR; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; THROMBOCYTE COUNT;

ADOLESCENT; ANTIGENS, CD34; BLOOD PLATELETS; BONE MARROW TRANSPLANTATION; CELL COUNT; CHILD; CHILD, PRESCHOOL; FEMALE; HAPLOTYPES; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA; MALE; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 71049193972     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22159     Document Type: Article

References (36)

1. Peters C, Matthes-Martin S, Fritsch G, et al. Transplantation of highly purified peripheral blood CD34+ cells from HLA-mismatched parental donors in 14 children: Evaluation of early monitoring of engraftment. Leukemia 1999;13:2070-2078.
2. Marks DI, Khattry N, Cummins M, et al. Haploidentical stem cell transplantation for children with acute leukaemia. Br J Haematol 2006;134:196-201. (Pubitemid 43893912)
3. Liu D, Huang X, Liu K, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematological malignancies in children. Biol Blood Marrow Transplant 2008;14:469-477.
4. Ogawa H, Ikegame K, Kaida K, et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis. Exp Hematol 2008;36:1-8. (Pubitemid 350266965)
5. Arpaci F, Tezcan I, Kuzhan O, et al. G-CSF-mobilized haploidentical peripheral blood stem cell transplantation in children with poor prognostic nonmalignant disorders. Am J Hematol 2008;83:133-136.
6. Lang P, Handgretinger R. Haploidentical SCT in children: An update and future perspectives. Bone Marrow Transplant 2008;42: S54-S59.
7. Ball LM, Bernardo ME, Roelofs H, et al. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 2007;110:2764-2767. (Pubitemid 47523204)
8. Reisner Y, Martelli MF. From 'megadose' haploidentical hematopoietic stem cell transplants in acute leukemia to tolerance induction in organ transplantation. Blood Cells Mol Dis 2008; 40:1-7.
9. Ortin M, Raj R, Kinning E, et al. Partially matched related donor peripheral blood progenitor cell transplantation in paediatric patients adding fludarabine and anti-lymphocyte gamma-globulin. Bone Marrow Transplant 2002;30:359-366. (Pubitemid 35203508)
10. Lang P, Greil J, Bader P, et al. Long-term outcome after haploidentical stem cell transplantation in children. Blood Cells Mol Dis 2004;33:281-287. (Pubitemid 39446500)
11. Kremens B, Basu O, Peceny R, et al. Allogeneic CD34+ -selected peripheral stem cell transplantation from parental donors in children with non-malignant diseases. Bone Marrow Transplant 2002;29:9-13. (Pubitemid 34126492)
12. Ogawa H, Ikegame K, Kaida K, et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis. Exp Hematol 2008;36:1-8. (Pubitemid 350266965)
13. Huang XJ, Liu DH, Liu KY, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006;38:291-297.
14. Luo XH, Chang YJ, Xu LP, et al. The impact of graft composition on clinical outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic SCT. Bone Marrow Transplant 2009;43: 29-36.
15. Xiao-Jun H, Lan-Ping X, Kai-Yan L, et al. HLA-mismatched/ haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: Improved outcomes in patients in accelerated phase and blast crisis phase. Ann Med 2008;40:444-455.
16. Lu DP, Dong L,Wu T, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrowtransplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006;107:3065-3073.
17. Marks R, Potthoff K, Hahn J, et al. Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: Particular activity against advanced hematologic malignancies. Blood 2008;112:415-425.
18. Huang XJ, Liu DH, Liu KY, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2008;42:295.
19. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974;18:295-304.
20. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft versus- host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204-217.
21. Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991;28:250-259.
22. Keever-Taylor CA, Klein JP, Eastwood D, et al. Factors affecting neutrophil and platelet reconstitution following T cell-depleted bone marrow transplantation: Differential effects of growth factor type and role of CD34(+) cell dose. Bone Marrow Transplant 2001;27:791-800. (Pubitemid 32496411)
23. 6 CD34+ cells/kg be considered the minimum threshold? Bone Marrow Transplant 2000;26:489-496.
24. Sartor MM, Garvin F, Antonenas V, et al. Failure to achieve a threshold dose of CD34+ CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation. Bone Marrow Transplant 2007;40:851-857. (Pubitemid 350020319)
25. Diaz MA, Vicent MG, Garcia-Sanchez F, et al. Long-term hematopoietic engraftment after autologous peripheral blood progenitor cell transplantation in pediatric patients: Effect of the CD34+ cell dose. Vox Sang 2000;79:145-150.
26. Kang Y, Chao NJ, Aversa F. Unmanipulated or CD34 selected haplotype mismatched transplants. Curr Opin Hematol 2008;15:561-567.
27. Koh LP, Rizzieri DA, Chao NJ. Allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors. Biol Blood Marrow Transplant 2007;13:1249-1267. (Pubitemid 47571038)
28. Handgretinger R, Klingebiel T, Lang P, et al. Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant 2001;27:777-783. (Pubitemid 32496409)
29. Rizzieri DA, Koh LP, Long GD, et al. Partially matched, nonmyeloablative allogeneic transplantation: Clinical outcomes and immune reconstitution. J Clin Oncol 2007;25:690-697.
30. Liu Y, Chen S, Yu H. Standardization and quality control in flow cytometric enumeration of CD34(+) cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2000;8:302-306.
31. Zaucha JM, Zellmer E, Georges G, et al. G-CSF-mobilized peripheral blood mononuclear cells added to marrow facilitates engraftment in nonmyeloablated canine recipients: CD3 cells are required. Biol Blood Marrow Transplant 2001;7:613-619. (Pubitemid 33130594)
32. Champlin RE. T-cell depletion for bone marrow transplantation: Effects on graft rejection, graft-versus-host disease, graft-versus-leukemia, and survival. Cancer Treat Res 1990;50:99-111.
33. Deeg HJ, Storb R,Weiden PL, et al. Abrogation of resistance to and enhancement of DLA-nonidentical unrelated marrow grafts in lethally irradiated dogs by thoracic duct lymphocytes. Blood 1979;53:552-557.
34. Urbano-Ispizua A, Rozman C, Pimentel P, et al. The number of donor CD3(+) cells is the most important factor for graft failure after allogeneic transplantation of CD34(+) selected cells from peripheral blood from HLA-identical siblings. Blood 2001;97: 383-387. (Pubitemid 32060321)
35. Anasetti C, Amos D, Beatty PG, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989; 320:197-204. (Pubitemid 19034144)
36. Galotto M, Berisso G, Delfino L, et al. Stromal damage as consequence of high-dose chemo/radiotherapy in bone marrow transplant recipients. Exp Hematol 1999;27:1460-1466. (Pubitemid 29409465)